Nuclear Medicine Communications最新文献

{"title":"Semiquantitative analysis of 18F-aluminum fluoride fibroblast activation protein inhibitor 42 PET/computed tomography in primary liver cancer and factors influencing imaging positivity rates.","authors":"Qi-Chang Wan, Mu-Hua Cheng, Liang-Jun Xie","doi":"10.1097/MNM.0000000000001994","DOIUrl":"10.1097/MNM.0000000000001994","url":null,"abstract":"<p><strong>Objectives: </strong>This study evaluated 18F-aluminum fluoride fibroblast activation protein inhibitor 42 (18F-AlF-FAPI-42) PET/computed tomography (CT) imaging characteristics in primary liver cancer (PLC) and analyzed detection rate determinants.</p><p><strong>Methods: </strong>Fifty-three untreated patients (76 lesions) with suspected PLC [hepatocellular carcinoma (HCC) or non-HCC subtypes] underwent 18F-AlF-FAPI-42 PET/CT. Maximum standardized uptake value (SUV max ) of lesions and mean SUV of adjacent normal liver tissue were measured to calculate target-to-background ratio (TBR). Patients were stratified by pathology, cirrhosis status, lesion size [small (3 cm), nodular (3-5 cm), massive (>5 cm)], lesion number, and alpha-fetoprotein (AFP).</p><p><strong>Results: </strong>Overall positivity rate was 86.8% (66/76 lesions). Non-HCC lesions showed significantly higher SUV max (15.6 vs. 10.3; P < 0.001) and TBR (12.6 vs. 3.9; P < 0.001) than HCC. Lesion size correlated with SUV max ( r = 0.54) and TBR ( r = 0.37) (both P < 0.001). HCC demonstrated lower detection than non-HCC (80.6 vs. 100%; P = 0.018), while cirrhotic patients showed reduced detection vs. noncirrhotic (80 vs. 96.8%; P = 0.034). Detection rates increased with lesion size: 72.0% (small), 80.0% (nodular), and 100% (massive) ( P = 0.004). Lesion number and AFP levels showed no significant impact. Subgroup analysis confirmed lesion size and pathological type as independent predictors ( P < 0.05), while cirrhosis showed no independent effect ( P > 0.05).</p><p><strong>Conclusion: </strong>18F-AlF-FAPI-42 PET/CT demonstrates high sensitivity for PLC, particularly for non-HCC subtypes and larger lesions. While smaller HCCs show reduced detection, cirrhosis doesn't significantly impair diagnostic performance, supporting its clinical utility in cirrhotic populations.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"753-759"},"PeriodicalIF":1.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144102239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bifunctional chelator-plerixafor complex for targeting CXCR4 receptors: radiolabeling, in-vitro, and preclinical study.","authors":"Tamanna Lakhanpal, Jaya Shukla, Rajender Kumar, Yogesh Rathore, Pankaj Malhotra, Alka Khadwal, Amanjit Bal, Bhagwant Rai Mittal","doi":"10.1097/MNM.0000000000001998","DOIUrl":"10.1097/MNM.0000000000001998","url":null,"abstract":"<p><strong>Objective: </strong>Overexpression of chemokine receptor subtype 4 (CXCR4) receptors is the root cause of the metastatic spread of various cancers. The use of CXCR4 antagonists as specific ligands to inhibit the CXCR4 interaction with its only natural ligand stromal cell derived factor-1α would benefit. Plerixafor is one such Food and Drug Administration approved CXCR4 antagonist used for hematopoietic stem cell mobilization in patients. Taking the specific advantage of low molecular weight, plerixafor conjugation with different bifunctional chelating agents, was optimized.</p><p><strong>Methods and results: </strong>Radiolabeling of the complex with 68 Ga radionuclide was standardized at pH (3-8), incubation time (5-30 min), temperature (25-100 °C), and volume (0.5-4.5 ml) followed by quality control checks: radionuclide, radiochemical purity, sterility, and pyrogenicity. In-vivo biodistribution studies were performed using gallium-68-diethylenetriamine pentacectic acid ( 68 Ga-DTPA)-plerixafor in normal rats. The molecular weights of DTPA- and 1,4,7-triazacyclononane-1,4,7-triacetic acid-conjugated plerixafor were 1087 and 1014 Da, respectively. Radiolabeling yield of DTPA conjugated plerixafor was greater than or equal to 99% at pH 5.5; 10-15 min incubation at room temperature; and 2.5-4.5 ml maximum volume. Radionuclide and radiochemical purities were greater than or equal to 99%. Radiopharmaceuticals were sterile and pyrogen-free. Physiological uptake of 68 Ga-DTPA-plerixafor was noted in the spleen (~20% ID/g), liver (4-5% ID/g), blood pool (6-13% ID/g), and faster clearance via kidneys (18-19% ID) up to 180 min.</p><p><strong>Conclusion: </strong>Radiolabelled 68 Ga-DTPA-plerixafor has the potential as a diagnostic carrier molecule for imaging in-vivo CXCR4 expression.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"726-737"},"PeriodicalIF":1.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144310225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of perfusion on ventilation/perfusion scan after balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension: expert opinion versus guidance by reference chart.","authors":"Diederik P Staal, Mitch C J van Thor, Ruth G M Keijsers, Monique M C van Buul, Joyce Peper, Daniel A F van den Heuvel, Sanne Boerman, Johannes J Mager, Martijn C Post","doi":"10.1097/MNM.0000000000001996","DOIUrl":"10.1097/MNM.0000000000001996","url":null,"abstract":"<p><strong>Objective: </strong>Balloon pulmonary angioplasty (BPA) is frequently used in chronic thromboembolic pulmonary hypertension (CTEPH)/chronic thromboembolic pulmonary disease (CTED). Nevertheless, noninvasive pulmonary perfusion imaging after BPA is scarce. In this study, change in perfusion on ventilation/perfusion (V/Q) scan after BPA was assessed and correlated with clinical outcomes.</p><p><strong>Methods: </strong>Retrospectively, all consecutive patients with CTEPH/CTED patients who completed BPA and received planar V/Q scans baseline and 6 months follow-up were included. Perfusion was evaluated using gestalt interpretation and semiquantitative calculation of the pulmonary vascular obstruction (PVO) index, with obligatory use of the lung segment reference chart. Interobserver variability was assessed for both methods, and the correlation between PVO index and clinical parameters was tested.</p><p><strong>Results: </strong>Thirty-three patients with CTEPH/CTED (mean age: 60.4 ± 14.7 years, 70% female) underwent 127 BPA procedures. Gestalt interpretation showed improved perfusion in 79% of all patients, and PVO index decreased significantly compared with baseline (45 ± 15-35 ± 15%; P  < 0.001). The gestalt method showed a weak level of agreement ( k  = 0.32; P  = 0.06), and the PVO method showed a moderate to strong reliability ( R2  : 0.71, P  < 0.001). The PVO index showed a significant ( P  < 0.001) but weak correlation with log N-terminal probrain natriuretic peptide, mean pulmonary artery pressure, and pulmonary vascular resistance ( R2  : 0.26, 0.24, and 0.18, respectively).</p><p><strong>Conclusion: </strong>Perfusion on V/Q scan significantly improved after BPA in patients with CTEPH/CTED. Semiquantitative calculation of PVO was more reliable in comparison to gestalt interpretation, however, clinical parameters showed only a weak correlation with the PVO index.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"711-719"},"PeriodicalIF":1.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12240140/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144151350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumoricidal dosing approach with parenchymal sparing using voxel-based dosimetry in 90 Y glass microspheres treatment of hepatocellular carcinoma.","authors":"Burcu E Akkaş, Cihan Şin, Elife Akgün, Tevfik Guzelbey, Cagri Erdim, Özge Vural Topuz, Emrah Birol, Özgür Kilickesmez, Meryem Kaya","doi":"10.1097/MNM.0000000000001991","DOIUrl":"10.1097/MNM.0000000000001991","url":null,"abstract":"<p><strong>Objective: </strong>We aimed to evaluate the effect of tumor absorbed doses (TAD) on treatment response in patients with hepatocellular cancer (HCC) treated with 90 Y glass microspheres. We aimed to define a cutoff value for complete response (CR).</p><p><strong>Methods: </strong>The voxel-based dosimetry for the treatment of 66 HCC lesions in 56 patients was analyzed retrospectively. Nineteen patients had BCLC A, 23 patients had BCLC B, and 14 patients had BCLC C disease. Treatments were grouped as selective (radiation segmentectomy and super-selective segmentectomy, n:49) and nonselective (palliative treatments for tumors occupying >2 segments, n:17). Treatment response was evaluated by mRECIST criteria, defined as CR, partial response (PR), stable lesion (SL), and progressive lesion (PL). TAD associated with CR was analyzed.</p><p><strong>Results: </strong>TAD was 525 ± 222 Gy in our cohort. Fifteen lesions had CR, 28 had PR, eight remained stable, and 15 lesions progressed. CR, PR, SL, and PL rates for selective vs. nonselective treatments were 31, 42, 12, and 14% vs. 0, 41, 11, and 47% for nonselective treatments, respectively ( P :0.01). TAD was significantly associated with treatment response. Receiver operating characteristic analysis showed TAD > 475 Gy predicted CR with 100% sensitivity and 68% specificity (area under the curve = 0.83, P  < 0.001). Overall survival declined as treatment response deteriorated. None of the patients had radiation-induced liver dysfunction on follow-up (6-21 months).</p><p><strong>Conclusion: </strong>Higher TAD is crucial for CR. Segmentectomy with TAD > 475 Gy is associated with favorable response and better survival in HCC patients. Even for palliative treatments, as high as reasonably tolerated doses must be applied to achieve a favorable response.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"692-699"},"PeriodicalIF":1.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144006872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The use of simulations to study the effect of acquisition schemes and quantification methods using positron emission tomography: an 18 F-Fallypride study.","authors":"Mohlapoli S Mohlapholi, Alex Doruyter, Michael Mix, Chris Trauernicht, Annare Ellmann, James Warwick, Patrick Dupont","doi":"10.1097/MNM.0000000000001995","DOIUrl":"10.1097/MNM.0000000000001995","url":null,"abstract":"<p><strong>Introduction: </strong>This computational study evaluates the accuracy of kinetic models and acquisition schemes in dynamic PET imaging using simulations of 18 F-fallypride PET in the human brain on the real-world data.</p><p><strong>Methods: </strong>We employed a 2-tissue 4-k model to generate ideal tissue curves for three regions (putamen, thalamus, and temporal cortex) and a reference region (cerebellum), incorporating a simulated metabolite-corrected input function. Realistic measurements were simulated over a 240-min PET scan by defining acquisition protocols (frame timings and durations), modeling tracer decay, and adding noise. Distribution volume ratios (DVRs) were calculated using the Logan reference analysis and the simplified reference tissue model (SRTM), the relative error in DVR was also assessed across various acquisition protocols. Rate constants from the 2-tissue model were varied, and Bland-Altman analysis was quantified to determine bias relative to ground-truth DVR.</p><p><strong>Results: </strong>Results indicate that, under low noise conditions, the Logan reference method performed optimally with a protocol involving a 60-min dynamic scan, a 60-min break, a 30-min scan, another 60-min break, and a final 30-min scan. In noisier conditions, the SRTM yielded the best results with a 150-min effective scan time incorporating three breaks.</p><p><strong>Conclusion: </strong>These findings highlight the impact of noise and acquisition strategy on model performance, informing optimal PET imaging protocols.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"760-771"},"PeriodicalIF":1.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144234750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Monte Carlo simulation of radiation dose to infant patients from urine-contaminated diapers during diuretic renal scintigraphy.","authors":"Yonggang Lu, Sachin Kumbhar, Yu Liu, Nghia Jack Vo, Marjorie Bessette Baker, Jing Qi","doi":"10.1097/MNM.0000000000002000","DOIUrl":"10.1097/MNM.0000000000002000","url":null,"abstract":"<p><strong>Objectives: </strong>To quantify the radiation doses received by infants from urine-contaminated diapers during diuretic renal scintigraphy examinations, a Monte Carlo dose simulation method integrated with advanced image processing techniques was proposed and evaluated.</p><p><strong>Methods: </strong>Organ-specific dose coefficients with radiation sourcing from diapers were calculated by a Monte Carlo dose simulation package (GAMOS 6.1.0) with the International Commission on Radiological Protection reference infant phantoms modified to include diapers as computational phantoms. Doses absorbed by organs of patients in the exams were estimated by multiplying the computed organ-specific dose coefficients by the cumulative activities of contaminated diapers estimated from time-series renal scintigraphy images. Data from 10 infant patients (five male and five female) who underwent renal scintigraphy exams were evaluated.</p><p><strong>Results: </strong>The dose coefficients of representative organs (mGy/Bq.s) were calculated to be 2.82E-13 (total body), 4.84E-13 (penis), 6.48E-14 (testes), 4.35E-14 (scrotum), and 6.75E-15 (prostate) for male infants; 4.37E-14 (total body), 6.71E-13 (uterus), 5.11E-14 (bladder), 3.19E-15 (ovaries), and 2.77E-15 (sigmoid) for female infants. Absorbed doses (mGy) in male patients from the evaluated patient data were quantified to be 1.94 (total body), 4.45E-01 (testes), 3.32E-01 (penis), 2.98 E-01 (scrotum), and 4.63 E-02 (prostate), and in female patients were 1.18 (total body), 1.81E-01 (uterus), 1.38 E-01 (bladder), 8.62E-02 (ovaries), and 7.49 E-02 (sigmoid).</p><p><strong>Conclusion: </strong>The study proposed and evaluated a method to quantify radiation dose from urine-contaminated diapers during renal scintigraphy exams in infants. The results indicated that the radiation dose from the contaminated diaper cannot be ignored, especially for radiation-sensitive organs such as testes and ovaries.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"700-710"},"PeriodicalIF":1.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144216445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic pitfalls in [ 68 Ga]Ga-DOTATATE PET/CT imaging: a systematic review.","authors":"Ahmed Saad Abdlkadir, Dhuha Al-Adhami, Mohammed Al Rammahi, Mohannad Badarneh, Salem Al Yasjeen, Khalid Al Busaidi, Aysar Khalaf, Haider Al-Alawi, Hasan Al-Alawi, Akram Al-Ibraheem","doi":"10.1097/MNM.0000000000001987","DOIUrl":"10.1097/MNM.0000000000001987","url":null,"abstract":"<p><p>[ 68 Ga]Ga-DOTA-Tyr3-octreotate ([ 68 Ga]Ga-DOTATATE) is an established somatostatin receptor imaging agent that has demonstrated superior efficacy in visualizing neuroendocrine tumors (NETs) and meningiomas compared with traditional [ 111 In]In-octreotide imaging. Despite its enhanced affinity and sensitivity, [ 68 Ga]Ga-DOTATATE imaging is not without challenges. To date, numerous diagnostic pitfalls and false-positive findings have been reported. This systematic review investigates the currently recognized diagnostic pitfalls in [ 68 Ga]Ga-DOTATATE positron imaging. A systematic literature search was conducted using PubMed, Scopus, and Web of Science databases, with the most recent update on 8 March 2024. Two authors screened the titles and abstracts of retrieved articles and selected studies based on predefined inclusion and exclusion criteria. Qualitative analysis of 70 included research articles, encompassing 199 patients, identified 234 diagnostic pitfalls. Malignant neoplastic etiologies predominated, constituting 56% of pitfalls, followed by nononcologic pitfalls (32.1%), and benign oncologic tumors (11.9%). Anatomically, the head and neck region was the most frequent site for pitfalls (35.5%), followed by the musculoskeletal system (27.4%), abdomen (17.5%), and chest (16.6%). Pelvic-related pitfalls were least common, accounting for only 3% of cases. This study details potential diagnostic pitfalls, predominantly occurring in the head-neck regions - primary sites for meningiomas and paragangliomas. Understanding these diagnostic pitfalls is crucial for accurate diagnosis. Moreover, recognizing these diagnostic pitfalls may lead to novel applications of [ 68 Ga]Ga-DOTATATE beyond its conventional use in NETs and meningiomas, potentially expanding its diagnostic utility.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"651-661"},"PeriodicalIF":1.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144026573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retrospective analysis of neuroblastoma and pheochromocytoma therapy with I-131 metaiodobenzylguanidine at a reference oncology hospital in Brazil.","authors":"Matheus N Dos Santos, Filipe Dos S Soares, Renata C M Felix, Priscilla B Pujatti","doi":"10.1097/MNM.0000000000001993","DOIUrl":"10.1097/MNM.0000000000001993","url":null,"abstract":"<p><strong>Background: </strong>Metaiodobenzylguanidine (MIBG) is a norepinephrine analogue with high affinity and specificity for the norepinephrine transporter. I-131-labeled MIBG (I-131 MIBG) is a therapeutic radiopharmaceutical used in selected cases of refractory or metastatic neuroblastoma and pheochromocytoma, tumors that overexpress the norepinephrine transporter. While the use of I-131 MIBG in neuroblastoma and pheochromocytoma therapy is well-established, the literature shows significant variability in treatment response, regarding the dose of the radiopharmaceutical, previous therapies administered, and the clinical condition of the patients involved in the studies. To contribute to the current literature, this study analyzed the use of I-131 MIBG at a cancer treatment institution in Brazil.</p><p><strong>Methods: </strong>Retrospective, observational, single-center study was conducted, with a descriptive and exploratory character, involving patients diagnosed with neuroblastoma and pheochromocytoma treated with I-131 MIBG from 2010 to 2025. Demographic, clinical, and laboratory parameters were collected before and after I-131 MIBG therapy. The outcome was determined through survival analysis.</p><p><strong>Results: </strong>Thirty-two patients were treated with I-131 MIBG, including 24 patients with neuroblastoma and six patients with pheochromocytoma. Leukocytes and platelets showed a reduction, and aspartate aminotransferase (AST) levels exhibited a significant increase posttherapy in patients with neuroblastoma. Survival rate was 84% in patients with pheochromocytoma and 55% in patients with neuroblastoma in the first year following I-131 MIBG therapy; however, both groups showed a gradual reduction in the cumulative survival rates, reaching 20% after 5 years.</p><p><strong>Conclusion: </strong>I-131 MIBG was primarily used for the treatment of neuroblastoma in pediatric patients, and pheochromocytomas in adults. Anemia, leukopenia, thrombocytopenia, and increased serum AST were the main adverse events, and cumulative survival rates were 20% after 5 years.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"682-691"},"PeriodicalIF":1.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144151371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PET image nonuniformity texture features for metastasis risk prediction in osteosarcoma.","authors":"Muath Almaslamani, Byung-Hyun Byun, Kanghyon Song, Chang-Bae Kong, Sang-Keun Woo","doi":"10.1097/MNM.0000000000001989","DOIUrl":"10.1097/MNM.0000000000001989","url":null,"abstract":"<p><strong>Objective: </strong>PET image analysis provides tumor heterogeneity data related to neoadjuvant chemotherapy response (NACR) and metastatic risk in osteosarcoma. Ki-67 expression is used to predict metastasis. The accuracy of prediction models with image quantitative features can be improved by including genetic information. Here, we aimed to evaluate the accuracy of a combination of heterogeneous 18 F-fluorodeoxyglucose PET image texture features and Ki-67 expression as predictive indicators of metastasis.</p><p><strong>Methods: </strong>PET images and clinical data of 82 patients with osteosarcoma before and after treatment were collected. Quantitative features were extracted from the PET images obtained before treatment, and the area under the receiver operating characteristic curve (AUC) for NACR and metastatic event was calculated. Relative risk and odds analyses of the quantitative features of the entire image were performed. Kaplan-Meier survival analysis was performed to determine the relationship between image quantitative features and clinical information. The machine learning prediction model was evaluated using valid image quantitative features and various algorithms of the univariate analysis.</p><p><strong>Results: </strong>Forty-seven image textures were obtained. The AUC values were 0.504-0.62 for NACR and 0.510-0.598 for metastatic events. The NACR and metastatic risk were related to the gray-level run length matrix (GLRLM) run length nonuniformity (RLNU) (relative risk: 1.3846, P  = 0.0138 for NACR; relative risk: 2.1284, P  = 0.049 for metastatic event) in the univariate analysis. The accuracy of the prediction model using the random forest algorithm with GLRLM RLNU, Ki-67 expression, and NACR was 0.91 for metastatic risk. NACR and metastatic risk were predicted with high accuracy using the nonuniformity in PET image texture.</p><p><strong>Conclusion: </strong>Combining PET image texture nonuniformity with Ki-67 expression and clinical data can enhance the accuracy of metastasis prediction in osteosarcoma. This multimodal approach may support metastasis risk prediction in osteosarcoma and aid in personalized treatment planning.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"738-745"},"PeriodicalIF":1.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143972581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in the application of 18 F-sodium fluoride PET in the assessment of atherosclerosis.","authors":"Yan Wang, Mingyuan Hou, Taiyang Zuo","doi":"10.1097/MNM.0000000000001988","DOIUrl":"10.1097/MNM.0000000000001988","url":null,"abstract":"<p><p>Atherosclerosis serves as the primary cause of cardiovascular diseases (CVDs), with its pathological processes encompassing lipid deposition, inflammatory responses, and calcification. Traditional imaging techniques, such as computed tomography angiography and MRI, are primarily utilized for detecting arterial stenosis and calcified plaques, yet they face challenges in accurately assessing plaque activity and instability. 18 F-sodium fluoride PET ( 18 F-NaF PET) offers a novel approach for plaque activity and stability assessment by labeling and quantifying arterial wall calcification. This article reviews the advances in the application of 18 F-NaF PET in the assessment of atherosclerosis.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"662-672"},"PeriodicalIF":1.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144031342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}